NCT05921760View on ClinicalTrials.gov

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 23, 2023

Primary Completion Date

November 21, 2024

Study Completion Date

November 21, 2024

Conditions
IDH1-mutant Cholangiocarcinoma
Interventions
DRUG

Ivosidenib

ivosidenib taken once daily

DRUG

Recommended Combination Dose (RCD) of ivosidenib

The RCD of ivosidenib taken once daily

DRUG

Nivolumab

Nivolumab taken by intravenous infusion

DRUG

Ipilimumab

Ipilimumab taken by intravenous infusion

Trial Locations (5)

21231

Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore

94158

UCSF - Medical Center at Mission Bay, San Francisco

Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco

02215

Dana Farber Cancer Institute, Boston

NW1 2PG

UCLH, London

All Listed Sponsors
collaborator

Institut de Recherches Internationales Servier

OTHER

lead

Servier Bio-Innovation LLC

INDUSTRY